Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
14. Juli 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update
21. Mai 2020 16:00 ET
|
PAVmed Inc.
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...
Biofrontera provides clinical development updates
19. Februar 2020 05:45 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
20. März 2019 10:50 ET
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...